Tarsus Pharmaceuticals, Inc.
Clinical trials sponsored by Tarsus Pharmaceuticals, Inc., explained in plain language.
Tarsus Pharmaceuticals, Inc.
TARS
NASDAQ
Develops therapies for ophthalmic and dermatologic conditions.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye gel could ease rosacea symptoms Results expected Dec 2026 (estimated) May already have reported ↗